Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

On May 15, 2025 , the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market.

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

A low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, polyols) diet can improve patients' irritable ...

Cash and cash equivalents as of March 31, 2025 were $102.3 million. Due in part to the strategic restructuring and ...

Janux Therapeutics, Inc. (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for ...

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Two ...